Basal cell carcinoma (BCC) is the most common cancer worldwide. While most BCC cases respond to surgical management, complex BCC often presents treatment challenges for patients unsuitable for, or refractory to, surgery and radiotherapy-limiting treatment options. Hedgehog pathway inhibitors (HHI) have emerged as an important treatment option for patients with complex BCC-providing a durable treatment modality and improved clinical outcomes. We present a case series of 10 patients with complex BCC treated with sonidegib, an oral HHI, at a dose of 200 mg once daily for a mean duration of 6 months and a mean follow-up of 7 months. Of these patients, sonidegib monotherapy was curative in eight cases. Of the remaining two patients, treatment with sonidegib arrested tumor progression and decreased tumor size to a point where surgical removal was straightforward. The positive treatment response we observed supports use of sonidegib as an effective treatment option for patients with complex BCC.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9285371 | PMC |
http://dx.doi.org/10.1111/dth.15217 | DOI Listing |
Infect Drug Resist
December 2024
Department of Medical Laboratory, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, People's Republic of China.
J Mark Access Health Policy
December 2024
Department of Midwifery, School of Health Sciences, University of Western Macedonia, 50200 Ptolemaida, Greece;
This study evaluates the efficiency of public hospitals in Greece during the COVID-19 epidemic in 2020, using Data Envelopment Analysis (DEA) and the Analytical Hierarchy Process (AHP). Faced with unprecedented pressure from increased demand for medical services, these hospitals had to adapt quickly while playing a crucial role in supporting local economies, similar to the effect of tourism on rural economies. This study reveals that, despite average efficiency scores of 83% for result-oriented models (BCC) and 65% for constant return models (CCR), inefficiencies of scale emerged under the pressures of the pandemic.
View Article and Find Full Text PDFJ Contemp Brachytherapy
October 2024
Department of Radiation Oncology, Cancer Institute, Imam Khomeini Hospital Complex, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Purpose: Non-melanoma skin cancer (NMSC) is the most prevalent cancer worldwide, particularly affecting head and neck region. Surgical excision, especially Moh's microsurgery, is the gold standard for treatment. However, certain patients' factors, such as age, comorbidities, and tumor location, require alternative therapies.
View Article and Find Full Text PDFInt J Biol Macromol
December 2024
National Glycoengineering Research Center and NMPA Key Laboratory for Quality Research and Evaluation of Carbohydrate-based Medicine, Shandong University, 72 Binhai Road, Qingdao 266237, China. Electronic address:
The Burkholderia cepacia complex (Bcc) is a group of phenotypically similar but genotypically diverse Gram-negative bacteria that pose a significant threat to public health worldwide. Due to the absence of effective therapies, the development of an effective vaccine against Bcc infection is urgently needed. Lipopolysaccharide (LPS) O-antigens of B.
View Article and Find Full Text PDFAdv Mater
December 2024
State Key Laboratory for Mechanical Behavior of Materials, Xi'an Jiaotong University, Xi'an, 710049, P. R. China.
High strength and large ductility, leading to a high material toughness (area under the stress-strain curve), are desirable for alloys used in cryogenic applications. Assisted by domain-knowledge-informed machine learning, here a complex concentrated FeCoNiAlTa alloy is designed, which uses L1 coherent nanoprecipitates in a high volume fraction (≈65 ± 3 vol.%) in a face-centered-cubic (FCC) solid solution matrix that undergoes FCC-to-body-centered-cubic (BCC) phase transformation upon tensile straining.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!